Autonomix Medical (NASDAQ:AMIX) Stock Rating Raised to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Autonomix Medical (NASDAQ:AMIX) from a strong sell rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Autonomix Medical presently has an average rating of “Hold” and an average target price of $42.00.

Autonomix Medical Price Performance

Shares of NASDAQ:AMIX opened at $3.78 on Friday. The company’s fifty day moving average price is $5.59 and its 200-day moving average price is $6.84. The firm has a market capitalization of $3.67 million, a price-to-earnings ratio of -0.09 and a beta of -0.96. Autonomix Medical has a one year low of $2.44 and a one year high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. As a group, equities research analysts expect that Autonomix Medical will post -20.17 EPS for the current year.

About Autonomix Medical

Autonomix Medical, Inc is a medical device company developing catheter-based technologies intended to diagnose and treat conditions involving the peripheral nervous system. The company’s platform uses a miniature sensing chip integrated into a catheter to detect and measure nerve signals in targeted areas of the body.

Autonomix is initially focused on applications in pain management, including the detection and treatment of nerves associated with chronic and cancer-related pain. Its technology is designed to help physicians identify relevant nerves more precisely and guide procedures such as targeted nerve ablation or other therapeutic interventions.

The company’s development programs remain subject to clinical testing, regulatory review and authorization before any products can be broadly commercialized.